9 min.

Niki Karavitaki on the risk of brain tumours after radiotherapy for pituitary adenoma The Lancet Diabetes & Endocrinology in conversation with

    • Geneeskunde

Niki Karavitaki talks with The Lancet Diabetes & Endocrinology about the risk of a second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma.

Read the full article:
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Niki Karavitaki talks with The Lancet Diabetes & Endocrinology about the risk of a second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma.

Read the full article:
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

9 min.